Neurenati Therapeutics

Montreal, Canada

Neurenati Therapeutics is a biotechnology company that develops therapeutics for gastrointestinal rare diseases.

$1.7M raised

Apr 2024

Seed

Biotechnology Medical Therapeutics

Top Investors

Investissement QuebecGenson Capital

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Neurenati Therapeutics

How much funding has Neurenati Therapeutics raised?

Neurenati Therapeutics has raised $1.7M in total funding. The most recent round was Seed. The last funding was announced in April 2024.

Who are Neurenati Therapeutics's investors?

Neurenati Therapeutics's investors include Investissement Quebec, Genson Capital.

Where is Neurenati Therapeutics headquartered?

Neurenati Therapeutics is headquartered in Montreal, Canada.

What does Neurenati Therapeutics do?

Neurenati Therapeutics is a biotechnology company that develops therapeutics for gastrointestinal rare diseases.

What stage is Neurenati Therapeutics at?

Neurenati Therapeutics is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 18, 2024.

MLA

"Neurenati Therapeutics — Funding & Investors." VCBacked, April 18, 2024, https://www.vcbacked.co/company/neurenati-therapeutics. Accessed June 17, 2026.

APA

VCBacked. (2024). Neurenati Therapeutics — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/neurenati-therapeutics

Wikipedia (cite web)

{{cite web |title=Neurenati Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neurenati-therapeutics |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 18, 2024.